Oncorus Competitors

Oncorus (NASDAQ:ONCR) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Cassava Sciences, as provided by MarketBeat.

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential upside of 1.39%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Cassava Sciences.

Institutional & Insider Ownership

26.7% of Cassava Sciences shares are held by institutional investors. 13.7% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncorus and Cassava Sciences' top-line revenue, earnings per share and valuation.

Profitability

This table compares Oncorus and Cassava Sciences' net margins, return on equity and return on assets.

Oncorus (NASDAQ:ONCR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Aclaris Therapeutics, as provided by MarketBeat.

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Aclaris Therapeutics.

Institutional & Insider Ownership

59.1% of Aclaris Therapeutics shares are held by institutional investors. 8.2% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncorus and Aclaris Therapeutics' top-line revenue, earnings per share and valuation.

Oncorus has higher earnings, but lower revenue than Aclaris Therapeutics.

Profitability

This table compares Oncorus and Aclaris Therapeutics' net margins, return on equity and return on assets.

Summary

Oncorus beats Aclaris Therapeutics on 6 of the 9 factors compared between the two stocks.

Oncorus (NASDAQ:ONCR) and Antibe Therapeutics (NASDAQ:ATBPD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Antibe Therapeutics, as provided by MarketBeat.

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Antibe Therapeutics.

Valuation & Earnings

This table compares Oncorus and Antibe Therapeutics' top-line revenue, earnings per share and valuation.

Antibe Therapeutics has higher revenue and earnings than Oncorus.

Profitability

This table compares Oncorus and Antibe Therapeutics' net margins, return on equity and return on assets.

Summary

Oncorus beats Antibe Therapeutics on 5 of the 7 factors compared between the two stocks.

Oncorus (NASDAQ:ONCR) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Arcutis Biotherapeutics, as provided by MarketBeat.

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 98.64%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Arcutis Biotherapeutics.

Valuation & Earnings

This table compares Oncorus and Arcutis Biotherapeutics' top-line revenue, earnings per share and valuation.

Institutional & Insider Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncorus and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Summary

Oncorus beats Arcutis Biotherapeutics on 4 of the 5 factors compared between the two stocks.

Oncorus (NASDAQ:ONCR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oncorus and Keros Therapeutics, as provided by MarketBeat.

Oncorus currently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Keros Therapeutics has a consensus price target of $78.00, suggesting a potential upside of 37.64%. Given Oncorus' higher possible upside, research analysts plainly believe Oncorus is more favorable than Keros Therapeutics.

Valuation and Earnings

This table compares Oncorus and Keros Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Institutional and Insider Ownership

58.4% of Keros Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncorus and Keros Therapeutics' net margins, return on equity and return on assets.

Oncorus (NASDAQ:ONCR) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oncorus and COMPASS Pathways, as provided by MarketBeat.

Oncorus currently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. COMPASS Pathways has a consensus price target of $70.75, suggesting a potential upside of 105.97%. Given Oncorus' higher possible upside, research analysts plainly believe Oncorus is more favorable than COMPASS Pathways.

Valuation and Earnings

This table compares Oncorus and COMPASS Pathways' gross revenue, earnings per share (EPS) and valuation.

Institutional and Insider Ownership

15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncorus and COMPASS Pathways' net margins, return on equity and return on assets.

Summary

COMPASS Pathways beats Oncorus on 3 of the 4 factors compared between the two stocks.